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ABSTRACT
Purpose To provide whole-body physiologically based phar-
macokinetic (PBPK) models of the potent clinical organic an-
ion transporter (OAT) inhibitor probenecid and the clinical
OAT victim drug furosemide for their application in
transporter-based drug-drug interaction (DDI) modeling.
Methods PBPK models of probenecid and furosemide were
developed in PK-Sim®. Drug-dependent parameters and
plasma concentration-time profiles following intravenous
and oral probenecid and furosemide administration were
gathered from literature and used for model development.
For model evaluation, plasma concentration-time profiles,
areas under the plasma concentration–time curve (AUC)
and peak plasma concentrations (Cmax) were predicted and
compared to observed data. In addition, the models were
applied to predict the outcome of clinical DDI studies.
Results The developed models accurately describe the
reported plasma concentrations of 27 clinical probenecid
studies and of 42 studies using furosemide. Furthermore, ap-
plication of these models to predict the probenecid-
furosemide and probenecid-rifampicin DDIs demonstrates
their good performance, with 6/7 of the predicted DDI
AUC ratios and 4/5 of the predicted DDI Cmax ratios within
1.25-fold of the observed values, and all predicted DDI AUC
and Cmax ratios within 2.0-fold.
Conclusions Whole-body PBPK models of probenecid and
furosemide were built and evaluated, providing useful tools
to support the investigation of transporter mediated DDIs.
KEY WORDS drug-drug interaction (DDI) . furosemide .
organic anion transporter (OAT) . physiologically based
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ABBREVIATIONS
AADAC Arylacetamide deacetylase
ADME Absorption, distribution, metabolism and excretion
AUClast Area under the plasma concentration-time curve
(AUC) from the time of drug administration to the
time of the last concentration measurement
Cmax Peak plasma concentration
DDI Drug-drug interaction
EMA European Medicines Agency
FDA U.S. Food and Drug Administration
GFR Glomerular filtration rate
GMFE Geometric mean fold error
MRD Mean relative deviation
MRP Multidrug resistance-associated protein
OAT Organic anion transporter
OATP Organic anion transporting polypeptide
PBPK Physiologically based pharmacokinetics
Pgp P-glycoprotein
SLC Solute carrier
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INTRODUCTION
Many important drug transporters are members of the solute
carrier (SLC) family, which is widely expressed throughout the
human body and mediates influx or efflux of endogenous and
exogenous substrates (1). For the approval of new drugs, the
U.S. Food and Drug Administration (FDA) and the European
Medicines Agency (EMA) require various in vitro, and in many
cases, clinical studies to characterize the transporter mediated
drug-drug interaction (DDI) potential of investigational drugs.
Based on the outcome of these investigations, recommenda-
tions for dose adjustments are given in the accompanying label
of a new drug (2,3).
Organic anion transporter (OAT) 1 and OAT3 are mem-
bers of the SLC transporter family (SLC22A6, SLC22A8) and
recognized as important drug transporters from the perspec-
tive of their potential to be involved in clinically relevant
DDIs. OAT1 and OAT3 are predominantly expressed in
the kidney at the basolateral membrane of proximal tubule
cells (4), where they facilitate the uptake of endogenous (e.g. p-
aminohippurate, estrone sulfate) and exogenous (e.g. diuretic
drugs) organic anions from the blood into the proximal tubule
cells (5), from where they can be secreted into the nephron
lumen for excretion with the urine. Several polymorphisms
have been identified and investigated; however, variants of
OAT1 or OAT3 have not been shown to significantly impact
the renal clearance of OAT substrates in clinical studies (6,7).
To characterize the OAT mediated DDI potential, the FDA
recommends furosemide as clinical OAT1/OAT3 substrate
and probenecid as clinical OAT1/OAT3 inhibitor (8). In ad-
dition, probenecid can also be used to investigate organic
anion transporting polypeptide (OATP) 1B1 mediated DDIs
(9).
OATP1B1, another clinically relevant member of the SLC
transporter family (SLCO1B1), is exclusively expressed at the
sinusoidal membrane of hepatocytes, where it is responsible
for the uptake of endogenous (e.g. bile acids) and exogenous
(e.g. statins, rifampicin) organic anions from the blood into the
hepatocytes (10,11). As probenecid also inhibits OATP1B1,
the prediction of the probenecid-rifampicin DDI was included
into the presented study, to further evaluate the performance
of the probenecid model as a DDI perpetrator.
Physiologically based pharmacokinetic (PBPK) modeling is
encouraged and supported by the FDA and EMA as a valu-
able tool to quantitatively describe and predict the pharma-
cokinetics of drugs, to evaluate DDI potential and to support
clinical study design, dose selection and labeling during drug
development (2,3,12–14). The objectives of this study were to
provide whole-body PBPK models of probenecid and furose-
mide, incorporating the transporters and enzymes involved in
the pharmacokinetics of these drugs. In vitro measurements
were used to parametrize the respective incorporated process-
es. The models were built and evaluated to adequately predict
the plasma concentration-time profiles and the fractions ex-
creted unchanged in urine. Furthermore, the models were
used to predict probenecid DDIs, with probenecid as potent
clinical OAT1/OAT3 inhibitor (8,15), moderate OATP1B1
inhibitor (9), weak inhibitor of multidrug resistance-associated
protein (MRP) 4 (16) and weak inhibitor of uridine 5′-diphos-
pho-glucuronosyltransferase (UGT) 1A9 (in-house measure-
ment), furosemide as clinical OAT1/OAT3 substrate and ri-
fampicin as OATP1B1 substrate. The comprehensive
Electronic Supplementary Material (ESM) to this manuscript
provides detailed information on the developed PBPK mod-
els, including all model parameters and a complete documen-
tation of the extensive model evaluation. The model files will




PBPK modeling was performed with the open source PK-
Sim® and MoBi® modeling software (version 8.0, part of
the Open Systems Pharmacology Suite (17,18), www.open-
systems-pharmacology.org). Published plasma concentration-
time profiles were digitized using GetData Graph Digitizer
(version 2.26.0.20, S. Fedorov) (19). Parameter optimizations
were accomplished with the Monte Carlo algorithm as well as
the Levenberg-Marquardt algorithm using the “multiple ran-
dom starting values” function implemented in PK-Sim®. The
final optimizations were run using the Levenberg-Marquardt
algorithm. PK parameter analysis and calculation of model
performance measures was performed with R (version 3.6.2,
The R Foundation for Statistical Computing) and graphics
were compiled with R and RStudio (version 1.2.5033,
RStudio, Inc., Boston, MA, USA). Sensitivity analysis was
performed using the implemented Sensitivity Analysis tool in
PK-Sim® (20).
PBPK Model Building
PBPK model building was started with an extensive literature
search to collect physicochemical parameters, information on
absorption, distribution, metabolism and excretion (ADME)
processes and clinical studies of intravenous and oral admin-
istration of probenecid and furosemide in single- and multiple
dose regimens.
To build the datasets for PBPK model development, the
reported observed plasma concentration-time profiles were
digitized and divided into a training dataset for model build-
ing and a test dataset for model evaluation. Model input
parameters that could not be informed from experimental
reports were optimized by fitting the model simultaneously
Pharm Res (2020) 37: 250250 Page 2 of 14
to the observed data of all studies assigned to the training
dataset. To limit the parameters to be optimized duringmodel
building, the minimal number of processes necessary to mech-
anistically describe the pharmacokinetics and DDIs of the
modeled drugs were implemented into the models. If two
transporters show very similar expression patterns and affinity
for the same compound, optimizing the transport rate con-
stants of both transporters would lead to identifiability issues.
Therefore, only the transporter with the higher affinity for the
respective substrate was implemented, to describe a transport
that probably is accomplished by both transporters in vivo.
Model evaluation was carried out based on the clinical data
of the test dataset. Descriptive (training dataset) and predictive
(test dataset) performance of themodel for all analyzed clinical
studies is transparently documented in the ESM.
Virtual Individuals
The PBPK models were built based on data from healthy
individuals, using the reported sex, ethnicity and mean values
for age, weight and height from each study protocol. If no
demographic information was provided, the following default
values were substituted: male, European, 30 years of age,
73 kg body weight and 176 cm body height (characteristics
from the PK-Sim® population database (21,22)). ADME
transporters and enzymes were implemented in accordance
with literature, using the PK-Sim® expression database to
define their relative expression in the different organs of the
body (23). Table S7.0.1 summarizes all system-dependent
parameters on the implemented transporters and enzymes.
Virtual Population Characteristics
To predict the variability of the simulated plasma
concentration-time profiles, virtual populations of 100 indi-
viduals were generated, consisting of either European or
Asian individuals. The percentage of female individuals and
the ranges of age, weight and height were set according to the
reported demographics. If not specified, virtual populations
containing 100 male subjects 20–50 years of age were used,
with body weight and height restrictions from the PK-Sim®
population database (22). For details on the study populations
see Tables S2.2.1, S3.2.1, S5.2.1 and S6.2.1.
In the generated virtual populations, organ volumes, tissue
compositions, blood flow rates, etc. were varied by an imple-
mented algorithm within the limits of the International
Commission on Radiological Protection (ICRP) (21,22) or
Tanaka (24) databases. In addition, the reference concentra-
tions of the implemented transporters and enzymes were log-
normally distributed around their mean values, using reported
variabilities for their expression from the PK-Sim® database
(25) or from literature. Table S7.0.1 summarizes the modeled
transporters and enzymes with their reference concentrations
and variabilities.
As the clinical plasma concentration data from literature is
mostly reported as arithmetic means ± standard deviation,
population prediction arithmetic means and 68% prediction
intervals were plotted, that correspond to a range of ±1 stan-
dard deviation around the mean assuming normal
distribution.
PBPK Model Evaluation
Model performance was evaluated using various methods.
The population predicted plasma concentration-time pro-
files were compared to the data observed in the clinical
studies. Furthermore, predicted plasma concentrations of
all studies were compared to the observed plasma concen-
trations in goodness-of-fit plots. In addition, the model
performance was evaluated by comparison of predicted
to observed areas under the plasma concentration-time
curve (AUC) from the time of drug administration to
the time of the last concentration measurement (AUClast)
and peak plasma concentration (Cmax) values. As quanti-
tative measures of the model performance, the mean rel-
ative deviation (MRD) of all predicted plasma concentra-
tions (Eq. 1) and the geometric mean fold error (GMFE)
of all predicted AUClast and Cmax values (Eq. 2) were
calculated. MRD and GMFE values ≤2 characterize an
adequate model performance.











where cpredicted, i = predicted plasma concentration, cob-
served, i = corresponding observed plasma concentration
and k = number of observed values.


















where predicted PK parmeteri = predicted AUClast or
Cmax, observed PK parameteri = corresponding observed
AUClast or Cmax and m = number of studies.
Furthermore, sensitivity analysis results were assessed. A
detailed description of the sensitivity calculation is provided
in the ESM.
PBPK DDI Modeling
As an additional means of model evaluation, the DDI perfor-
mance of the developed models was assessed. To model the
probenecid-furosemide DDI, inhibition of OAT3, UGT1A9
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and MRP4 by probenecid was implemented. To predict the
probenecid-rifampicin DDI, inhibition of OATP1B1 by pro-
benecid was incorporated (Fig. 1). The rifampicin model ap-
plied was developed by Hanke et al. (26) and is freely available
in the Open Systems Pharmacology repository on GitHub
(27). The model includes rifampicin transport via OATP1B1
and P-glycoprotein (Pgp), metabolism via the arylacetamide
deacetylase (AADAC), as well as auto-induction of
OATP1B1, Pgp and AADAC (26). The good DDI perfor-
mance of the model was demonstrated in many different
applications (26,28–31). Mathematical implementation of
the DDI processes is specified in Section 1 of the ESM.
Inhibition constants characterizing the inhibition of
OAT3, UGT1A9 (in-house measurement) and OATP1B1
by probenecid were taken from in vitro experimental reports
(9,15). Short descriptions of the respective in vitro assay con-
ditions are provided in Sections 5.1 and 6.1 of the ESM. To
describe the competitive inhibition of MRP4 by probenecid,
the corresponding inhibition constant was optimized during
the furosemide PBPK model parameter identification, using
the clinical data of one of the probenecid-furosemide interac-
tion studies (32) (see Table S5.2.1). The DDI parameter values
are listed in the probenecid drug-dependent parameter table
(Table S2.3.1).
PBPK DDI Performance Evaluation
All DDI predictions were evaluated by comparison of pre-
dicted versus observed victim drug plasma concentration-time
profiles alone and during co-administration, DDI AUClast ra-
tios and DDI Cmax ratios (Eq. 3).
DDI PK parameter ratio
¼ PK parametervictim drug during co−administration
PK parametervictim drug alone
ð3Þ
where PK parameter = AUClast or Cmax.
As quantitative measure of the DDI prediction accuracy,
GMFEs of the predicted DDI AUClast ratios and DDI Cmax
ratios were calculated according to Eq. 2.
RESULTS
PBPK Model Building and Evaluation
The probenecid PBPK model was developed using 27 differ-
ent clinical studies, including intravenous (single dose) and oral
(single- and multiple dose) administration. A complete list of
the clinical studies used in the presented analysis is provided in
Table S2.2.1. In addition, five studies reported fraction ex-
creted unchanged in urine profiles following oral administra-
tion. In the intravenous studies, probenecid was administered
in doses of 464–1860 mg. In the oral studies, probenecid was
administered in doses of 250–2000 mg. The training dataset
included 11 probenecid plasma concentration-time profiles
and one fraction excreted unchanged in urine profile. The
final probenecid model applies uptake into kidney cells via
OAT3, glucuronidation mainly in the renal cells by






Fig. 1 Probenecid DDIs. Schematic illustration of the modeled DDIs with
probenecid as OAT3, UGT1A9, MRP4 and OATP1B1 perpetrator drug,
furosemide as OAT3, UGT1A9 and MRP4 victim drug and rifampicin as
OATP1B1 victim drug. The red solid lines indicate competitive inhibition,
the red dotted line indicates non-competitive inhibition by probenecid. The
black dashed lines indicate transport or metabolism. Drawings by Servier
Medical Art, licensed under CC BY 3.0. MRP4: multidrug resistance-
associated protein 4, OAT3: organic anion transporter 3, OATP1B1: or-
ganic anion transporting polypeptide 1B1, UGT1A9: uridine 5′-diphospho-
glucuronosyltransferase 1A9.
Fig. 2 Probenecid plasma concentrations. (a) Selected population
predictions of probenecid plasma concentration-time profiles compared to
observed data in semilogarithmic (upper panel) and linear plots (lower panel).
Observed data are shown as dots ± standard deviation (42,54,55).
Population simulation arithmetic means are shown as lines; the shaded areas
illustrate the predicted population variation (Q16 – Q84). (b) Predicted com-
pared to observed probenecid plasma concentration values of all analyzed
clinical studies. The solid line marks the line of identity. The dotted lines
indicate 1.25-fold, the dashed lines indicate 2-fold deviation. Details on dosing
regimens, study populations and literature references are summarized in
Table S2.2.1. iv: intravenous, po: oral, sd: single dose, tab: tablet.
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which was modeled as a reduction of the glomerular filtration
rate (GFR fraction <1). The drug-dependent parameters are
summarized in Table S2.3.1.
Population predicted compared to observed plasma
concentration-time profiles of selected studies as well as the
probenecid goodness-of-fit plot with the predicted plasma
concentrations of all studies are presented in Fig. 2.
Semilogarithmic and linear plots of the plasma profiles of all
27 clinical studies included in the analysis are shown in the
ESM. Population predicted compared to observed fraction
excreted unchanged in urine profiles are also presented in
the ESM. Table S2.5.1 lists the MRD values of all 27 studies.
The correlation of predicted and observed probenecid
AUClast and Cmax values is presented in Fig. 3, further dem-
onstrating the good model performance with 27/27 predicted
AUClast and 18/18 predicted Cmax values within 2-fold of the
observed data. The individual values, mean GMFE values
and ranges are listed in Table S2.5.2.
The sensitivity analysis results of a simulation of 500 mg
probenecid twice daily as a tablet are illustrated in Fig. S2.5.3.
Applying a threshold of 0.5, the probenecid model is sensitive
to the values of the UGT1A9 catalytic rate constant
(optimized) and Michaelis-Menten constant (literature value),
the probenecid fraction unbound in plasma (literature value),
the OAT3 catalytic rate constant (optimized) and the proben-
ecid lipophilicity (optimized).
The furosemide PBPK model was developed using 42 dif-
ferent clinical studies, including intravenous (single dose) and
oral (single- and multiple dose) administration. A complete list
of the clinical studies used in the presented analysis is provided
in Table S3.2.1. In addition, 27 studies reported fraction ex-
creted unchanged in urine profiles following intravenous and
oral administration. In the intravenous studies, furosemide
was administered in doses of 20–80 mg. In the oral studies,
furosemide was administered in doses of 1–80 mg. The train-
ing dataset included 14 furosemide plasma concentration-
time profiles, 11 fraction excreted unchanged in urine profiles
and one plasma concentrat ion-t ime prof i le with
corresponding fraction excreted unchanged in urine data of
furosemide during co-administration of probenecid (32). The
final furosemide model applies uptake into kidney cells via
OAT3, glucuronidation by UGT1A9, secretion into urine
via MRP4 and glomerular filtration. The drug-dependent
parameters are summarized in Table S3.3.1.
Population predicted compared to observed plasma
concentration-time profiles of selected studies as well as the
furosemide goodness-of-fit plot with the predicted plasma con-
centrations of all studies are presented in Fig. 4.
Semilogarithmic and linear plots of the plasma profiles of all
a b
Fig. 3 Probenecid AUClast and Cmax values. Predicted compared to observed probenecid (a) AUClast and (b) Cmax values of all analyzed clinical studies.
The solid line marks the line of identity. The dotted lines indicate 1.25-fold, the dashed lines indicate 2-fold deviation. Details on dosing regimens, study
populations and literature references are summarized in Table S2.2.1. The individual AUClast and Cmax values, mean GMFE values and ranges are listed in
Table S2.5.2.AUClast: area under the plasma concentration-time curve from the time of drug administration to the time of the last concentration measurement,
Cmax: peak plasma concentration.
Fig. 4 Furosemide plasma concentrations. (a) Selected population
predictions of furosemide plasma concentration-time profiles compared to
observed data in semilogarithmic (upper panel) and linear plots (lower panel).
Observed data are shown as dots ± standard deviation (56–58). Population
simulation arithmetic means are shown as lines; the shaded areas illustrate the
predicted population variation (Q16 – Q84). (b) Predicted compared to ob-
served furosemide plasma concentration values of all analyzed clinical studies.
The solid line marks the line of identity. The dotted lines indicate 1.25-fold, the
dashed lines indicate 2-fold deviation. Details on dosing regimens, study pop-
ulations and literature references are summarized in Table S3.2.1. iv: intrave-
nous, po: oral, qd: once daily, sd: single dose, sol: solution, tab: tablet.
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42 clinical studies included in the analysis are shown in the
ESM. Population predicted compared to observed fraction
excreted unchanged in urine profiles are also presented in
the ESM. Table S3.5.1 lists the MRD values of all 42 studies.
The correlation of predicted and observed furosemide
AUClast and Cmax values is presented in Fig. 5, further dem-
onstrating the good model performance with 41/42 predicted
AUClast and 24/25 predicted Cmax values within 2-fold of the
observed data. The individual values, mean GMFE values
and ranges are listed in Table S3.5.2.
The sensitivity analysis results of a simulation of 80 mg
furosemide once daily as a tablet are illustrated in Fig.
S3.5.3. Applying a threshold of 0.5, the furosemide model is
sensitive to the values of furosemide fraction unbound in plas-
ma (literature value) and the OAT3 catalytic rate constant
(optimized).
PBPK DDI Modeling and Evaluation
The developed PBPK models were applied to model the
probenecid-furosemide and probenecid-rifampicin DDIs
and the DDI performance was evaluated using the clinical
data of six studies investigating the probenecid-furosemide
DDI and one study of the probenecid-rifampicin DDI. For
all studies, plasma concentration-time profiles of the victim
drugs, administered alone and during probenecid co-admin-
istration, were predicted and compared to observed data. In
addition, four studies of the probenecid-furosemide DDI
reported fraction excreted unchanged in urine profiles, allow-
ing the comparison of predicted and observed urinary
excretion under control and DDI conditions. Administration
protocols, study population details and references of the clin-
ical DDI studies are listed in Tables S5.2.1 and S6.2.1.
To predict the probenecid-furosemide DDI, competitive
inhibition of OAT3 (Ki = 5.41 μmol/l) (15) and non-
competitive inhibition of UGT1A9 (Ki = 242.0 μmol/l) (in-
house measurement) by probenecid were implemented using
interaction parameter values measured in vitro. As no informa-
tion regarding the inhibition of MRP4 could be obtained, the
Ki to describe the competitive inhibition of MRP4 (Ki =
87.4 μmol/l) by probenecid was optimized during the param-
eter identification of the furosemide model. To predict the
probenecid-rifampicin DDI, competitive inhibition of
OATP1B1 (Ki = 39.8 μmol/l) (9) was implemented using an
interaction parameter value measured in vitro.
The coupled models adequately describe and predict all
furosemide and rifampicin plasma concentration-time pro-
files, as well as fraction excreted unchanged in urine profiles
of furosemide, under control conditions and during probene-
cid co-administration, over the full range of reported DDI
administration protocols. Population predicted compared to
observed plasma profiles of furosemide and rifampicin, ad-
ministered alone and during the DDIs, are presented in
Fig. 6 (selected DDI studies). Semilogarithmic and linear plots
of all 7 clinical DDI studies included in the analysis are shown
in Sections 5.3 and 6.3 of the ESM. Predicted compared to
observed furosemide fraction excreted unchanged in urine
profiles, administered alone and during probenecid co-admin-
istration, are presented in the ESM.
ba
Fig. 5 Furosemide AUClast and Cmax values. Predicted compared to observed furosemide (a) AUClast and (b) Cmax values of all analyzed clinical studies.
The solid line marks the line of identity. The dotted lines indicate 1.25-fold, the dashed lines indicate 2-fold deviation. Details on dosing regimens, study
populations and literature references are summarized in Table S3.2.1. The individual AUClast and Cmax values, mean GMFE values and ranges are listed in
Table S3.5.2.AUClast: area under the plasma concentration-time curve from the time of drug administration to the time of the last concentration measurement,
Cmax: peak plasma concentration.
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The correlation of predicted and observed DDI AUClast
ratios and DDI Cmax ratios of all analyzed clinical DDI studies
is shown in Fig. 7, further demonstrating the good DDI per-
formance with all predicted DDI ratios within 2-fold of the
observed data. The individual ratios, mean GMFE values and
ranges for both DDI combinations are listed in Table I.
DISCUSSION
The newly developed whole-body PBPK models for proben-
ecid and furosemide accurately describe the observed plasma
concentration-time profiles and fraction excreted unchanged
in urine data over the full range of reported doses and admin-
istration protocols. Furthermore, these models adequately de-
scribe the available clinical data from probenecid-furosemide
and probenecid-rifampicin clinical DDI studies.
Various other PBPKmodels of probenecid and furosemide
with different applications have been published previously
(33–38). For probenecid, three PBPK models are available
describing DDIs with drugs that are OAT substrates.
However, none of these analyses considered the probenecid-
furosemide DDI or extended the model to include UGT1A9,
MRP4 or OATP1B1 inhibition (33–35). The previously de-
veloped furosemide PBPKmodels were not built or evaluated
for use in DDI prediction (36–38).
Development of the probenecid model was particularly
challenging. The number of published clinical studies is low
and the quality of the available data varies considerably, as
probenecid was approved in the late 1940s. Hence, careful
consideration of the study protocols and the presented data
was required, and studies in patients or elderly volunteers, stud-
ies with co-medication and studies using others than the mar-
keted formulation were excluded for probenecid model devel-
opment. In addition, information on the ADME processes that
govern the pharmacokinetics of probenecid is very limited.
Probenecid shows a low solubility and permeability, indicat-
ing an important role of transporters in its absorption and dis-
tribution. However, neither in vitro nor in vivo studies describing
transporters involved in probenecid absorption, organ uptake,
secretion or reabsorption are available in literature. Therefore,
probenecid absorption was described by optimization of the
passive transcellular intestinal permeability (optimized value:
3.97 · 10−4 cm/min, lipophilicity based calculated value: 3.12
· 10−6 cm/min). The uptake of probenecid into the kidney,
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Kenwright 1973 − Rifampicin control
Kenwright 1973 − with probenecid
Rifampicin − po, 300 mg qd (tab)
Fig. 6 DDI plasma concentration-time profiles. Selected population predictions of the victim drug plasma concentration-time profiles compared to
observed data for the (a, b) probenecid-furosemide and (c) probenecid-rifampicin DDIs in semilogarithmic (upper panel) and linear plots (lower panel).
Observed data are shown as dots ± standard deviation (32,59,60). Population simulation arithmetic means are shown as lines; the shaded areas illustrate the
corresponding predicted population variation (Q16 – Q84). Details on dosing regimens, study populations and literature references are summarized in
Tables S5.2.1 and S6.2.1. iv: intravenous, po: oral, qd: once daily, sd: single dose, tab: tablet.
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to be mediated by OAT3. The parameters (KM, kcat) to de-
scribe this transport were optimized during parameter identifi-
cation (see Table S2.3.1). Furthermore, a low renal clearance
(42) and fraction excreted unchanged in urine of only 0.3% to
5% (43,44) are reported, indicating tubular reabsorption. Due
to our current lack of knowledge regarding transporters that
may contribute to probenecid reabsorption, the GFR fraction
was optimized to 0.03. This reduced GFR fraction substitutes
for the implementation of active reabsorption processes of pro-
benecid (20) and correctly captures the low probenecid fraction
excreted unchanged in urine.
In the clinical studies conducted by Vree et al. (43,44), pro-
benecid tablets were broken in half prior to oral administra-
tion. The corresponding plasma concentration-time profiles
display an earlier time to peak plasma concentration (Tmax)
of 1.6 h compared to the other clinical studies with a Tmax of
3.3 h. Given the low solubility of probenecid it is possible that
the broken tablets show a different dissolution behavior,
resulting in faster release and absorption. Therefore, a differ-
ent dissolution profile was used to describe the studies by
Vree et al. (43,44). The parameters to model the two different
dissolution profiles are listed in Table S2.3.1.
Similar to probenecid, furosemide also demonstrates low
solubility and permeability and is classified as a BCS class IV
drug (45). Therefore, transporters play an essential role in
furosemide absorption, distribution and elimination.
Furosemide bioavailability is highly variable (37%–83%)
(46), and influenced by dosage form and fasted/fed state of
the patient (46). For the absorption of furosemide,
Flanagan et al. postulate a saturable active transport process
and passive diffusion with paracellular contribution in Caco-2
cells (47). As no further information on transporters that may
contribute to the absorption of furosemide is available, ab-
sorption was modeled as passive transcellular (5.06 ·
10−7 cm/min) and paracellular (2.32 · 10−6 cm/min) intesti-
nal permeability. These processes together allow a rapid ab-
sorption in the small intestine to describe the early furosemide
Tmax of 1.0–1.5 h (46), while limiting the furosemide absorp-
tion in the large intestine. Other crucial transport processes
take place in the kidney, which is the main organ for furose-
mide metabolism and excretion (fraction excreted unchanged
in urine: 20%–80% (46)).
Uptake of furosemide into renal cells in vivo is probably
facilitated via OAT1 and OAT3. Both transporters are
predominantly expressed in the kidney (48) and show a similar
affinity to furosemide (OAT1 furosemide KM= 38.9 μmol/l,
OAT3 furosemideKM= 21.5 μmol/l (49)).Without addition-
al information to distinguish the furosemide transport via
these two transporters, the furosemide OAT1 and OAT3
transport rate constants would be highly correlated in a model
parameter optimization. To avoid indentifiability issues, renal
uptake of furosemide was incorporated via OAT3 only, as a
substitute for transport by both, OAT1 and OAT3. The pro-
benecid inhibition potency towards these transporters is also
similar (probenecid OAT1 Ki = 11.4 μmol/l, probenecid
OAT3 Ki = 5.41 μmol/l (15) and the DDI was predicted via
inhibition of OAT3. Furosemide metabolism was modeled
using UGT1A9 (50). The pronounced urinary excretion is









































Fig. 7 DDI AUClast and Cmax ratios. Predicted compared to observed (a) DDI AUClast ratios and (b) DDI Cmax ratios of the probenecid-furosemide and
probenecid-rifampicin DDIs. The solid line marks the line of identity. The dotted lines indicate 1.25-fold, the dashed lines indicate 2-fold deviation. The curved
grey lines show the prediction acceptance limits proposed by Guest et al. (61). Details on dosing regimens, the individual DDI AUClast and DDI Cmax ratios, mean
GMFE values and ranges are listed in Table I.AUClast: area under the plasma concentration-time curve from the time of drug administration to the time of the last
concentration measurement, Cmax: peak plasma concentration, DDI: drug-drug interaction.
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secretion. Renal secretion was incorporated via MRP4
(51,52), based on in vitro furosemide transport measurements.
In the goodness-of-fit plot, there seems to be an underpre-
diction of the lower furosemide plasma concentrations for two
of the intravenous studies (Rupp 1974 and Waller 1982).
These are the only two studies that published furosemide plas-
ma concentrations later than 6 h after intravenous dosing, and
they did not report their lower limits of quantification. The
model is therefore not qualified for the prediction of plasma
concentrations later than 6 h after intravenous administration
of furosemide. However, this does not affect the prediction of
higher plasma concentrations and AUClast values, and the
developed model shows a good performance, with 41/42 pre-
dicted AUClast and 24/25 predicted Cmax values within 2-fold
of the observed data.
To model the probenecid-furosemide DDI, inhibition of
OAT3 alone, using published in vitro inhibition parameters,
was not sufficient to describe the clinically observed data.
Therefore, inhibition of UGT1A9 and MRP4 were added
to adequately capture the impact of probenecid on the
furosemide pharmacokinetics. Inhibition parameter values
for OAT3 (15) and UGT1A9 (in-house measurement) were
available from in vitro studies. Van Aubel et al. reported MRP4
inhibition by probenecid (16), but so far, no inhibition param-
eter values have been published. Therefore, competitive
MRP4 inhibition was assumed and the Ki value was opti-
mized during parameter identification of the furosemidemod-
el. Applying the inhibition of OAT3, UGT1A9 and MRP4,
all reported plasma concentration time-profiles and fraction
excreted unchanged in urine profiles of furosemide during
Table 1 Predicted and Observed DDI AUClast Ratios and DDI Cmax Ratios with Mean GMFE Values and Ranges
Probenecid administration Victim drug administration DDI AUClast ratio DDI Cmax ratio Reference








500 po (−), qid (D1-D3) 40 iv (bolus), sd (D4) 2 2.52 2.83 0.89 – – – 3.0 Homeida 1977 (62)
1000 po (−), sd (D4)
1000 po (tab), bid (D1) 40 iv (3 min), sd (D1) 1 2.29 3.34 0.69 – – – 4.0 Smith 1980 (59)
GMFE 1.29 (1.12–1.45) –
2/2 with GMFE ≤ 2 –
Oral furosemide
1000 po (tab), bid (D1) 1 po (sol), sd (D1) 1 2.73 2.82 0.97 1.43 1.33 1.08 12.0 Wiebe 2020 (32)
1000 po (tab), bid (D1) 40 po (sol), sd (D1) 1 2.73 3.15 0.87 1.43 1.48 0.97 12.0 Wiebe 2020 (32)
1000 po (tab), sd (D1) 40 po (tab), sd (D1) 1 2.56 3.14 0.82 1.50 1.85 0.81 12.0 Shen 2019 (63)
1000 po (tab), sd (D1) 80 po (tab), sd (D1) 1 2.05 2.10 0.98 1.50 1.48 1.01 5.0 Vree 1995 (64)
GMFE 1.11 (1.02–1.22) 1.09 (1.01–1.23)
4/4 with GMFE ≤ 2 4/4 with GMFE ≤ 2
Overall GMFE of the probenecid-furosemide DDI 1.17 (1.02–1.45) 1.09 (1.01–1.23)
6/6 with GMFE ≤ 2 4/4 with GMFE ≤ 2
DDI ratios within in the prediction






2000 po (−), sd (D2) 300 po (tab), qd (D1-D2) 0.33 1.54 1.83 0.84 1.26 2.34 0.54 11.0 Kenwright 1973 (60)
1500 po (−), sd (D2)a
Overall GMFE of the probenecid-rifampicin DDI 1.19 1.85
1/1 with GMFE ≤ 2 1/1 with GMFE ≤ 2
DDI ratios within in the prediction
success limits of Guest et al. (61)
1/1 DDI AUClast
ratio
0/1 DDI Cmax ratio
a 2000mg probenecid 0.33 h before and 1500mg 6 h after rifampicin administration,AUClast: area under the plasma concentration-time curve from the time of
drug administration to the time of the last concentration measurement, bid: twice daily, Cmax: peak plasma concentration,D: day of administration,DDI: drug-
drug interaction, GMFE: geometric mean fold error, iv: intravenous, obs: observed, po: oral, pred: predicted, qid: four times daily, qd: once daily, route:
route of administration, sd: single dose, sol: solution, tab: tablet, Tlast: time of the last concentration measurement. GMFE values are means and ranges
Bold text marks the main results
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probenecid co-administration are well described by the pre-
sented models.
The probenecid-rifampicinDDI was predicted using a pro-
benecid OATP1B1 inhibition value measured with 2′,7′-
dichlorofluorescein as the substrate (9). For OATP1B1, it
has been demonstrated that its inhibition can strongly depend
on the employed substrate (53). However, since there are no
in vitro reports of probenecid OATP1B1 inhibition using ri-
fampicin, the DDI was predicted applying the probenecid
OATP1B1 Ki = 39.8 μmol/l measured with 2′,7′-dichloro-
fluorescein (9). Rifampicin is typically not used as OATP1B1
victim drug, but rather as OATP1B1/OATP1B3 inhibitor.
However, as the clinical data of this probenecid-rifampicin
trial were published, we wanted to utilize them to test our
probenecid model. In addition to OATP1B1/OATP1B3 in-
hibition, rifampicin is also inhibiting and inducing further
enzymes and transporters (13). Therefore, an impact of rifam-
picin on the perpetrator drug probenecid may have influ-
enced the results of this particular DDI administration proto-
col. Taking into account that the only available clinical study
has been published in 1973 and that the reported rifampicin
plasma concentrations show considerable standard deviations,
this DDI is also well described (see Fig. 6 and Table I).
CONCLUSIONS
The presented whole-body PBPK models of probenecid
and furosemide have been carefully built and evaluated
for their ability to predict the pharmacokinetics of these
drugs, using a multitude of clinical studies. In addition,
the models adequately describe the available clinical data
of the probenecid-furosemide and probenecid-rifampicin
DDIs and wi l l be shared in the Open Sys tems
Pharmacology PBPK model library (www.open-systems-
pharmacology.org) as tools to support the investigation of
the DDI potential of new compounds during drug
development. The ESM to this paper has been compiled
to serve as transparent and comprehensive documentation
of the probenecid and furosemide model development and
evaluation.
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